Conmind Medical Raises $29M in Series C to Advance Brain-Computer Interface and Cardio-Cerebral Integrated Care Platform
Conmind Medical, a China-based brain science and medical technology platform, has secured RMB 200 million...
Siemens Healthineers Partners with Shanghai’s Ruijin Hospital on World’s First AI-Powered Liver Fat Quantification Software
Siemens Healthineers AG (ETR: SHL) has entered into a strategic collaboration with Ruijin Hospital, a...
Zhuhai Rundu’s Higenamine Receives NMPA Approval as China’s First Category 1 Cardiac Stress Test Agent
China’s National Medical Products Administration (NMPA) has granted marketing approval for higenamine, a Category 1...
Youcare Pharma’s YKYY018 Inhalation Therapy Expands to COVID-19 Clinical Study Following RSV Development Success
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) announced it has received approval from China’s...
Binhui Biopharmaceutical Submits Hong Kong IPO Prospectus with Pioneering Oncolytic Virus Pipeline
Binhui Biopharmaceutical Co., Ltd. has submitted its initial public offering (IPO) prospectus to the Hong...
Youcare Pharma’s YKYY018 Inhalation Therapy Expands to COVID-19 Clinical Study Following RSV Development Success
Youcare Pharmaceutical Group (SHA: 688658) announced that its YKYY018 aerosolized inhalation formulation has received approval...
Shanghai Huilun Pharma Launches Hong Kong IPO with Integrated Pharmaceutical Platform and Robust Pipeline
Shanghai Huilun Pharmaceutical Co., Ltd. has successfully completed its initial public offering (IPO) on the...
Merck’s KEYTRUDA Receives EU Approval for Platinum-Resistant Ovarian Cancer in Combination Regimen
Merck & Co., Inc. (MSD, NYSE: MRK) announced that the European Commission has granted marketing...
Merck Launches Pivotal Phase 2b/3 Trial for MK-8748 Bispecific Antibody in Wet AMD Treatment
Merck & Co., Inc. (MSD, NYSE: MRK) announced the initiation of a pivotal Phase 2b/3...
Staidson Pharma Announces $182M Private Placement to Advance Innovative Biologics Pipeline
Staidson (Beijing) Pharmaceutical Co., Ltd. (SHE: 300204) announced plans to raise up to RMB 1.253...
Bio-Thera Solutions Gains NMPA Clearance for Phase I/II Trial of PD-1 Biosimilar BAT3306 Combined with Trop2 ADC BAT8008 in Advanced Solid Tumors
Bio-Thera Solutions, Ltd. (SHA: 688177) announced that China’s National Medical Products Administration (NMPA) has approved...
Zhifei Biological Renews Exclusive China Distribution Pact with Merck for Gardasil 9, Rotateq, and Pneumovax—Shifts to Demand-Driven Supply Model
Chongqing Zhifei Biological Products Co., Ltd. (SHE: 300122) announced the renewal of its long-standing supply,...
Xellar Biosystems Closes RMB 200M Series A Led by China Life Investment to Build 3D Bio Intelligence Platform
Xellar Biosystems, a U.S.-based pioneer in “AI + organ-on-a-chip” technology, announced the successful completion of...
Regeneron Partners with TriNetX in $200M Deal to Expand World-Leading Genomic-Phenotypic Data Platform
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced an exclusive strategic partnership with TriNetX, Inc., granting Regeneron...
AstraZeneca’s Imfinzi-Imjudo Combo with Lenvatinib and TACE Shows Significant PFS Benefit in Early-Stage Liver Cancer, EMERALD-3 Trial Reveals
AstraZeneca plc (NYSE: AZN) announced positive top-line results from the EMERALD-3 Phase III clinical trial,...
RemeGen Secures NMPA Approval for Phase I/IIa Trial of Bispecific ADC RC288 Targeting PSMA and B7H3 in Solid Tumors
RemeGen Ltd (HKG: 9995) announced it has received approval from China’s National Medical Products Administration...
Biocytogen and Sihuan Pharma Forge Strategic Partnership to Accelerate Innovative Drug Development Including Weight Management Therapies
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) announced a strategic partnership with Sihuan...
Sanli Pharmaceutical Transfers Marketing Rights for 16 Drugs to Hanfang Pharmaceutical in RMB 2 Million Deal
Guizhou Sanli Pharmaceutical Co., Ltd. (SHA: 603439) announced the transfer of marketing authorizations and comprehensive...
Fosun Pharma Secures NMPA Approval for Phase I Trial of HLX319, Biosimilar to Roche’s Phesgo for HER2-Positive Breast Cancer
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced it has received approval...
NMPA Approves World’s First Broad-Spectrum Tumor Imaging Agent 99mTc-3PRGD2 from Radio Medicinal
China’s National Medical Products Administration (NMPA) has granted approval for 99mTc-3PRGD2, a Category 1 radionuclide...